At a glance
ClinicalIndex Comparison RecordPhase 2Active· 15 enrolled
Drug / intervention
Duvelisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Intermittent Duvelisib Dosing in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
In Brief
A Phase 2 clinical trial evaluating Duvelisib for Recurrent Chronic Lymphocytic Leukemia and 3 related conditions. Active but no longer recruiting, targeting 15 participants across 3 sites.
Detailed Summary
This phase II trial studies how well duvelisib on an intermittent (irregular) dosing schedule works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving duvelisib on an intermittent schedule may result in similar effectiveness with less amount of severe side effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2Active
20202021202220232024202520262027
First PostedMay 2019
Enrollment StartMay 2020
Primary CompletionJul 2023
TodayJul 2026
Study CompletionOct 2026
First PostedMay 23, 2019
Enrollment StartMay 13, 2020
Primary CompletionJul 31, 2023
Study CompletionOct 26, 2026
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 7.1 years ago
Interventions
Duvelisibdrug
Given PO